Literature DB >> 11777839

Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay.

Tamara Rodríguez1, Miriam Lastre, Barbara Cedré, Judith del Campo, Gustavo Bracho, Caridad Zayas, Carlos Taboada, Miriam Díaz, Gustavo Sierra, Oliver Pérez.   

Abstract

The correlate of protection for serogroup B meningococci is not currently known, but for serogroup C it is believed to be the serum bactericidal assay (SBA). The current SBAs are labor intensive and the variations in protocols among different laboratories make interpretation of results difficult. A colorimetric SBA (cSBA), based on the ability of Neisseria meningitidis serogroup B to consume glucose, leading to acid production, was standardized by using group B strain Cu385-83 as the target. The cSBA results were compared to those obtained for a traditional colony-counting microassay (mSBA). Glucose and bromocresol purple pH indicator were added to the medium in order to estimate growth of cSBA target cell survivors through color change. Different variants of the assay parameters were optimized: growth of target cells (Mueller Hinton agar plates), target cell number (100 CFU/per well), and human complement source used at a final concentration of 25%. After the optimization, three other group B strains (H44/76, 490/91, and 511/91) were used as targets for the cSBA. The selection of the assay parameters and the standardization of cSBA were done with 13 sera from vaccinated volunteers. The titers were determined as the higher serum dilution that totally inhibited the bacterial growth marked by the color invariability of the pH indicator. This was detected visually as well as spectrophotometrically and was closely related to a significant difference in the growth of target cell survivors determined using Student's t test. Intralaboratory reproducibility was +/-1 dilution. The correlation between bactericidal median titers and specific immunoglobulin G serum concentration by enzyme immunoassay was high (r = 0.910, P < 0.01). The bactericidal titers generated by the cSBA and the mSBA were nearly identical, and there was a high correlation between the two assays (r = 0.974, P < 0.01). The standardized cSBA allows easy, fast, and efficient evaluation of samples.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11777839      PMCID: PMC119898          DOI: 10.1128/cdli.9.1.109-114.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  24 in total

1.  [Validation of an ELISA for the measurement of human IgG against serogroup B Neisseria meningitidis protein].

Authors:  X Ferriol Marchena; A M García Malberti; R Ochoa Azze; I Bravo Verde; R Blanco González; E Estrada González; M Nerey Olivares; J C Martínez Rodríguez
Journal:  Rev Cubana Med Trop       Date:  1999 May-Aug

2.  New Classification of Neisseria meningitidis by Means of Bactericidal Reactions.

Authors:  R Gold; F A Wyle
Journal:  Infect Immun       Date:  1970-05       Impact factor: 3.441

3.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

4.  Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Authors:  R Borrow; N Andrews; D Goldblatt; E Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide.

Authors:  A Bartoloni; F Norelli; C Ceccarini; R Rappuoli; P Costantino
Journal:  Vaccine       Date:  1995-04       Impact factor: 3.641

6.  Human bactericidal antibody response to meningococcal outer membrane protein vaccines.

Authors:  W D Zollinger; J Boslego; L O Frøholm; J S Ray; E E Moran; B L Brandt
Journal:  Antonie Van Leeuwenhoek       Date:  1987       Impact factor: 2.271

7.  Phenotypic and genotypic changes in a new clone complex of Neisseria meningitidis causing disease in The Netherlands, 1958-1990.

Authors:  R J Scholten; J T Poolman; H A Valkenburg; H A Bijlmer; J Dankert; D A Caugant
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

8.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

9.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors:  C E Frasch; J D Robbins
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  2 in total

1.  Opc expression, LPS immunotype switch and pilin conversion contribute to serum resistance of unencapsulated meningococci.

Authors:  Kerstin Hubert; Marie-Christin Pawlik; Heike Claus; Hanna Jarva; Seppo Meri; Ulrich Vogel
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

2.  A Novel Luminescence-Based Serum Bactericidal Assay for Vibrio cholerae Reduces Assay Variation, Is Time- and Cost-Effective, and Directly Measures Continuous Titer Values.

Authors:  Taylor A Wahlig; Ben J Brintz; Melanie Prettyman; Andrew S Azman; Daniel T Leung
Journal:  Am J Trop Med Hyg       Date:  2021-07-08       Impact factor: 2.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.